- Conditions
- Meibomian Gland Dysfunction (MGD)
- Interventions
- Vevye(Cyclosporine 0.1% Ophthalmic Solution)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 321
matching trials from the live ClinicalTrials.gov search.
- Conditions
- PCOS
- Interventions
- OCP + Metformin, OCP + Placebo, Metformin + Placebo
- Drug
- Lead sponsor
- Anuja Dokras
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Hershey, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Obstructive Sleep Apnea
- Interventions
- AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test
- Drug · Diagnostic Test
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more
- Conditions
- Gulf War Illness
- Interventions
- Curcumin, Resveratrol, Stinging Nettle
- Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Healthy
- Interventions
- Foods with beta-glucan from oats and barley
- Other
- Lead sponsor
- General Mills
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- HIV-1-infection
- Interventions
- PrEPsmart mobile app, Truvada
- Device · Drug
- Lead sponsor
- Public Health Foundation Enterprises, Inc.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration
- Drug · Biological · Other + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2038
- U.S. locations
- 238
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 185 more
- Conditions
- HIV Infection
- Interventions
- Text reminders, counseling, and link coordination, Standard of care - control arm
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Fort Worth, Texas
- Conditions
- Diabetes, Gestational
- Interventions
- nutritional counseling, self blood glucose monitoring
- Behavioral
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 7,381 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2013
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 13 more
- Conditions
- Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
- Interventions
- Rifaximin (drug)
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
- Interventions
- Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri
- Conditions
- Healthy Adult Male and Female Volunteers
- Interventions
- Low-frequency whole-body vibration mat
- Device
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Primary Membranous Nephropathy
- Interventions
- SNP-ACTH (1-39) Gel, Rituximab
- Drug
- Lead sponsor
- Cerium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Dimas, California • Tarzana, California + 15 more
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
- Interventions
- Technology Intensified
- Behavioral
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
- Procedure · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 275
- States / cities
- Birmingham, Alabama • Clovis, California • Concord, California + 195 more
- Conditions
- Hepatitis C
- Interventions
- HCV Screening
- Other
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 147,533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Baltimore, Maryland • Jackson, Mississippi
- Conditions
- Coronavirus, Corona Virus Infection
- Interventions
- Group 1 HCQ, Group 2 Placebo
- Drug
- Lead sponsor
- UnitedHealth Group
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
- Interventions
- Best Practice, Biospecimen Collection, Cisplatin, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, MnSOD Mimetic BMX-001, Placebo Administration, Questionnaire Administration
- Other · Procedure · Drug + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 153
- States / cities
- Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more
- Conditions
- Attention Deficit Disorders With Hyperactivity
- Interventions
- Pharmacogenomics report
- Diagnostic Test
- Lead sponsor
- Clinical and Translational Genome Research Institute, Inc.
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Hamilton, New Jersey • Mountainside, New Jersey • Toms River, New Jersey
- Conditions
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 13
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation
- Biological · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 119
- States / cities
- Beverly Hills, California • Los Angeles, California • Tarzana, California + 99 more
- Conditions
- Gingivitis
- Interventions
- Stannous Fluoride Dentifrice, Test Stannous Fluoride Dentifrice, Sodium monofluorophosphate dentifrice
- Drug
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Whitter, California
- Conditions
- Lumbar Post-Laminectomy Syndrome, Chronic Low Back Pain, Vertebral Compression Fracture, Failed Back Surgery Syndrome
- Interventions
- Continuous intrathecal prognostic infusion test, Bupivacaine, Fentanyl, Placebo, Intrathecal Drug Delivery System (IDDS)
- Other · Drug · Device
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio